Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

New compounds acting on cell proliferation, differentiation for keratinization disorders

Jan. 15, 2001

Phase II trial begins with Idec's antipsoriatic antibody IDEC-114

Jan. 12, 2001

Second phase II trial of HuMax-CD4 launched in patients with severe psoriasis

Jan. 11, 2001

Marketing agreement with Bioglan for Solaraze expanded by SkyePharma

Jan. 8, 2001

Abgenix plans to move ABX-IL-8 into phase IIb clinical trials for psoriasis

Jan. 8, 2001

Kyowa Hakko synthesizes phenylalanine esters intended for atopic dermatitis

Jan. 3, 2001

Pivotal trial of Ortec's donor site wound treatment shows promising results; PMA filing upcoming

Jan. 3, 2001

Chemokine receptor antagonists in GlaxoSmithKline portfolio

Jan. 2, 2001

Name change and recent TB4 research results announced by the former Alpha 1 Biomedicals

Jan. 2, 2001

Apthera for canker sores approved in Canada

Dec. 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...